Cyclophosphamide: all 1,616 studies that test it
Page 2 of 17. Open to participants first (256), then studies with results posted, then the rest; newest registration first within each.
- Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLRecruitingNCT06500273Phase 2
- LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT06472479Not applicable
- MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.RecruitingNCT06412497Phase 2
- Sequential Therapies Modeled on Evolutionary Dynamics for Breast CancerRecruitingNCT06409390Phase 2
- A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)RecruitingNCT06401330Phase 3
- Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid MalignanciesRecruitingNCT06383572Phase 1/2
- Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with Anti-Hu-associated Paraneoplastic Sensory NeuronopathyRecruitingNCT06373211Phase 2
- CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological MalignanciesRecruitingNCT06326463Phase 1
- Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for TransplantationRecruitingNCT06324266Phase 2/3
- Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune DiseasesRecruitingNCT06316076Phase 1
- Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast CancerRecruitingNCT06291064Phase 2
- Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)RecruitingNCT06255210Phase 2
- the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous NephropathyRecruitingNCT06245707Not applicable
- Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 BlockadeNot yet recruitingNCT06238245Phase 2
- PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of ImmunityRecruitingNCT06199427Phase 2
- Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPCRecruitingNCT06193486Phase 1
- B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic MalignanciesRecruitingNCT06191887Phase 1
- Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerRecruitingNCT06121570Phase 1
- Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerRecruitingNCT06121557Phase 1
- Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in ChildrenRecruitingNCT06099366Phase 2
- BRE-08 Phase II Study of CMC Regimen for Early Stage Breast CancerRecruitingNCT06085742Phase 2
- A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)RecruitingNCT06083922Phase 2
- Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline TherapyRecruitingNCT06083844Phase 2
- Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.RecruitingNCT06072612Phase 3
- Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)RecruitingNCT06066424Phase 1
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerRecruitingNCT06058377Phase 3
- CAR-T Cell Therapy for Desensitization in Kidney TransplantationRecruitingNCT06056102Phase 1
- Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid TumorsRecruitingNCT06047977Phase 1
- T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon CancerRecruitingNCT06043713Phase 1
- Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY TrialRecruitingNCT06042569Phase 2
- Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL AmyloidosisRecruitingNCT06022939Phase 3
- An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid TumorsRecruitingNCT06013111Phase 1
- A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With CancerRecruitingNCT05999994Phase 2
- The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.Not yet recruitingNCT05990985Not applicable
- Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerRecruitingNCT05981001Phase 1/2
- Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With YescartaRecruitingNCT05950802Phase 1
- A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLHRecruitingNCT05936086Not applicable
- Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMMNot yet recruitingNCT05909826Phase 2
- CAR T-cell Therapy in Patients With Renal DysfunctionRecruitingNCT05909059Phase 2
- Venetoclax Combined With Azactidine in the Treatment of ALALRecruitingNCT05901974Phase 2
- Delayed Tolerance Through Mixed ChimerismRecruitingNCT05900401Phase 1/2
- A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast CancerRecruitingNCT05862064Phase 3
- Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical TransplantRecruitingNCT05849207Phase 1
- Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's SyndromeRecruitingNCT05845723Phase 2
- Allo HSCT Using RIC and PTCy for Hematological DiseasesRecruitingNCT05805605Phase 2
- A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic AnemiaRecruitingNCT05757310Phase 1
- Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic TumorsRecruitingNCT05755854Phase 1
- HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05751044Phase 1/2
- HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05745714Phase 1/2
- A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)RecruitingNCT05736419Phase 2
- MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesRecruitingNCT05735717Phase 2
- Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid MalignanciesRecruitingNCT05705570Phase 1
- Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLLRecruitingNCT05702853Phase 1/2
- Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid TumorsRecruitingNCT05693844Phase 1/2
- HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid TumorsRecruitingNCT05681650Phase 1/2
- Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)RecruitingNCT05681260Phase 3
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingNCT05675410Phase 3
- HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05658640Phase 1/2
- EBV CAR-T Cells for Nasopharyngeal CarcinomaRecruitingNCT05654077Early Phase 1
- TIL Cells for the Treatment of the Advanced Solid Tumors PatientsNot yet recruitingNCT05649618Early Phase 1
- TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid TumorsNot yet recruitingNCT05648994Early Phase 1
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT05633615Phase 2
- Combination of CAR-DC Vaccine and ICIs in Malignant TumorsRecruitingNCT05631886Phase 1
- Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal CancersNot yet recruitingNCT05582590Phase 1
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
- Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed MedulloblastomaRecruitingNCT05535166Phase 2
- Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological MalignanciesRecruitingNCT05528887Phase 1
- Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)RecruitingNCT05521984Phase 1
- B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021RecruitingNCT05518383Phase 4
- Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKDRecruitingNCT05510323Phase 3
- Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same DonorRecruitingNCT05508009Phase 1/2
- MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LNRecruitingNCT05495893Phase 4
- Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor PatientsRecruitingNCT05468359Phase 1/2
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell TransplantationRecruitingNCT05436418Phase 1/2
- A Study for the Adjuvant Treatment of Breast CancerRecruitingNCT05420467Phase 4
- A Study for the Neoadjuvant Treatment of Breast CancerRecruitingNCT05420454Phase 4
- ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and PembrolizumabNot yet recruitingNCT05366062Phase 2
- Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic MalignanciesRecruitingNCT05327023Phase 1/2
- Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative RhabdomyosarcomaRecruitingNCT05304585Phase 3
- Allogeneic Hematopoietic Stem Cell Transplantation for 4/M NeuroblastomaNot yet recruitingNCT05303727Phase 2
- Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic CancersRecruitingNCT05296564Phase 1/2
- Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and LymphomaRecruitingNCT05294055Phase 2
- Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)RecruitingNCT05289167Phase 1/2
- RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast CancerRecruitingNCT05256745Phase 1/2
- Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCLNot yet recruitingNCT05238064Phase 1/2
- Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian CancerRecruitingNCT05225363Phase 1
- Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast CancerRecruitingNCT05159193Phase 3
- Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain CancerRecruitingNCT05106296Phase 1
- Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesRecruitingNCT05092451Phase 1/2
- A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) SyndromeRecruitingNCT05027945Phase 2
- GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor MalignanciesRecruitingNCT05003895Phase 1
- Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic MalignanciesRecruitingNCT04959175Phase 1/2
- Methods of T Cell Depletion Trial (MoTD)RecruitingNCT04888741Phase 2
- Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ LeukemiaRecruitingNCT04881240Phase 1
- Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic LeukemiaRecruitingNCT04825496Phase 1
- MicroRNA Profiles in Triple Negative Breast CancerRecruitingNCT04771871Phase 2
- Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma PatientsRecruitingNCT04757337Phase 3
- PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyRecruitingNCT04745949Phase 2
- Different Immunosuppressive Treatment in iMNRecruitingNCT04745728Phase 3
- Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell LymphomaRecruitingNCT04715217Phase 1/2